Somatuline Depot sNDA Submitted for Neuroendocrine Tumors

Share this content:
Somatuline Depot sNDA Submitted for Neuroendocrine Tumors
Somatuline Depot sNDA Submitted for Neuroendocrine Tumors

Ipsen Biopharmaceuticals announced that it has submitted a supplemental New Drug Application (sNDA) to the FDA for Somatuline Depot (lanreotide acetate) 120mg injection for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Somatuline Depot, a somatostatin analogue, inhibits the secretion of several endocrine, exocrine, and paracrine functions.

The NDA submission was supported by results from the CLARINET Phase 3 study which demonstrated the antiproliferative effect of Somatuline in the treatment of patients with GEP-NETs. Data from CLARINET showed that investigational treatment with Somatuline substantially prolonged time to disease progression or death vs. placebo (hazard ratio 0.47, P=0.0002). Safety data generated from the CLARINET study were consistent with the known safety profile of Somatuline.

RELATED: Endocrine Cancer Resource Center

Somatuline Depot is already approved for the long-treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.

For more information call (866) 837-2422 or visit Ipsen.com.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs